The economics of diseases and cures / Randall Waechter, editor.

Format:

Book

Contributor:

Waechter, Randall, editor.

Series:

Economic Issues, Problems and Perspectives

Language:

English

Subjects (All):

Medical economics.

Physical Description:

1 online resource (392 pages)

Place of Publication:

New York, New York : Nova Science Publishers, [2021]

Summary:

"This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"-- Provided by publisher.

Contents:

Intro

Contents

Foreword

Acknowledgments

List of Acronyms

Section A. Background and Measures

Chapter 1

The Economics of Diseases and Cures

Different Levels of Cures: Functional vs. Definitive

Measuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy

The Diffusion of Cures

The Value of Case Studies

References

Chapter 2

Tools and Assumptions

Data Sources

Timelines

Disease Categorization

Cure Categorization

Measures used to Assess the Value of Cures

Years of Potential Life Lost (YPLL)

Quality-Adjusted Life Years (QALY)

Disability-Adjusted Life Years (DALY)

Cure Impact

Calculation Assumptions

Section B. Infectious Diseases

Chapter 3

Acquired Immunodeficiency Syndrome (AIDS/HIV)

Disease Category

Disease Identification, Description, and Diagnostic Criteria

Disease Etiology (Cause)

Current Prevalence/Incidence

Estimated Undiagnosed and At-Risk

Disease Impact - Years of Potential Life Lost (YPLL)

Disease Impact - Disability Adjusted Life Years (DALY)

History of the Disease and Breakthroughs

Current Cure Status

Future Cure Obstacles

Research Development and Treatment Costs

HIV Cures: Anti-Retroviral Therapy (ART)

Cure Category

Cure Identification/Description

Cure History

Cure Science: Breakthroughs/Obstacles

Cure Science: Future Obstacles

Number of Patients Currently Being Treatment

Number of Patients Requiring Treatment

Impact of Treatment on Years of Potential Life Lost (YPLL)

Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY)

Cost of Treatment Using ART per Patient

Cost of Lifetime Treatment Using ART

Economic Impact - Value of Life Added

HIV Cures - Vaccination

Cure Science/Cure Obstacles

Phase I Trials.

Phase II Trials

Phase III Trials

Chapter 4

Influenza

Disease Description, Diagnosis, and Background

Estimated Undiagnosed/At-Risk

Research, Development and Treatment Costs

Influenza Cures: Vaccinations

Cure Science/Future Cure Obstacles and Targets

Number of Patients Currently Being Treated

Number of People Requiring Treatment

Impact of Treatment on Disability-adjusted Life Years (DALY/QALY)

Average Annual Total/Lifetime Cost of Vaccinations

Economic Impact - Value of Reduction in DALYs/Increase in QALYs

Influenza Cures: Antivirals

Number of Patients Being Treated

Number of Patients Requiring Antiviral Treatment

Impact of Antivirals on Years of Potential Life Lost (YPLL)

Impact of Antivirals on Disability-adjusted Life Years (DALYs/QALYs)

Average Annual Cost of Antivirals

Average Lifetime Cost of Antivirals

Chapter 5

Poliomyelitis

Estimated Undiagnosed/At-Risk.

Disease Impact - Years of Potential Life Lost (YPLL)

History of Disease and Breakthroughs

Polio Cures: Vaccines

Cure Identification/Description/Diagnostic Criteria

Cure Science: Future Obstacles and Targets

Impact of Polio Vaccine on Years of Potential Life Lost (YPLL)

Impact of Polio Vaccine on Disability Adjusted Life Years (DALYs/QALYs)

Cost of Vaccination

Economic Impact - Value of Years lived without Disability

Chapter 6

SARS-CoV-2

Transmission and Symptomatology

Testing

Hospitalizations

Mortality

Disease Impact- Disability Adjusted Life Years (DALY)

Research, Development and Treatment Cost

SARS-CoV-2 Cures: Behavioral Interventions

Black Death in 1347

Spanish Flu in 1918

Number of Patients Currently Being Treated/Requiring Treatment

Cost of Treatment

Economic Impact- Value Life Added

SARS-CoV-2 Cures: Vaccinations

Cure Category.

Cure Identification/Description

Economic Impact - Value Life Added

Economic Impact - Value of Reduction in DALYs/Increase QALYs

SARS-CoV-2 Cures: Antiviral Medications

Number of Patients Being Treated and Requiring Antiviral Treatment

Impact of Antivirals on Disability-Adjusted Life Years (DALYs/QALYs)

SARS-CoV-2 Cures: Immunosuppression Medications

Number of Patients Currently Being Treated and Requiring Treatment

Impact of Immunosuppressants on Years of Potential Life Lost (YPLL)

Impact of Immunosuppressants on Disability-Adjusted Life Years (DALY/QALY)

Economic Impact-Value of Reduction in DALYs/Increase QALYs

SARS-CoV-2 Cures: Convalescent Plasma Therapy

Number of Patients Currently Being Treated/Requiring Treatment.

Impact of Treatment on Years of Potential Life Lost (YPLL)

Economic Impact- Value of Reduction in DALYs/Increase QALYs

Section C. Chronic Diseases

Chapter 7

Alzheimer's Disease

Disease Etiology (Causes)

US Prevalence

US Incidence

Disease Impact - Disability Adjusted Life Years (DALYs)

Economic Impact - Years of Potential Life Lost (YPLL)

Economic Impact - Disability Adjusted Life Years (DALYs)

Chapter 8

Cardiovascular Disease

Disease Identification/Description/Diagnostic Criteria

Disease Prevalence/ Incidence

Estimated Undiagnosed/ At-Risk

Average Cost of Treating the Disease

Economic Impact - YPLL

Cardiovascular Disease Cures: Overview

Cardiovascular Disease Cures: Heart Surgery

Cure Identification/ Description

Cure History and Science: Breakthroughs/ Obstacles

Impact on Treatment on Years of Potential Life Lost (YPLL)

Average Cost of Cure Per Patient

Economic Impact - Value of Increased Years of Life Lived

Cardiovascular Disease Cures: Angioplasty

Cure Identification/ Description.

Notes:

Description based on print version record.

Includes index.

ISBN:

1-5361-9614-2

OCLC:

1250260753